SCHEMBL460303

SCHEMBL460303

COC(=O)C1CCC(Oc2ccc(C(=O)Nc3ccc(NC4(Cc5ccccc5)CCCC4)nn3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.47
LMNA P02545 4/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HSD17B10 Q99714 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
ADRB2 P07550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459338 0.80 DGAT1 (0.59) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL459339 0.80 DGAT1 (0.59) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL460301 0.78 DGAT1 (0.47) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL460302 0.78 DGAT1 (0.47) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL461184 0.77 DGAT1 (0.57) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL461185 0.77 DGAT1 (0.57) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL460793 0.74 DEGS1 (0.45) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL460794 0.74 DEGS1 (0.45) DGAT1LMNAALDH1A1RAB9ANPC1
SCHEMBL603236 0.73 DGAT1 (0.84) DGAT1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL601585 0.73 DGAT1 (0.84) DGAT1RAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595970-B1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI SA (FR) 2015-01-07 EP disclosed
US-20130137691-A1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI (FR) 2013-05-30 US disclosed
EP-2595970-A1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI (FR) 2013-05-29 EP disclosed
WO-2012011081-A1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI (FR) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137691-A1 DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS XDH, NOX3, OXA1L DGAT1 4152/4885LMNA 1049/4885ALDH1A1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.